Before the first biologic dose: what needs to happen?
If your rheumatologist proposes biologic treatment for rheumatoid arthritis, break the decision into clear steps. Biologics are a group of medicines that target parts of immune inflammation, not one medicine suitable for everyone. The first visit should establish why a change is being considered, which checks and precautions fit your situation, and how response will be reviewed. This is a preparation checklist, not a prescription for starting or switching treatment yourself [1,7].
Ask how active your RA is now, what the present plan has not achieved, and how improvement in swelling, movement and daily function will be measured. Your clinician weighs disease activity, infection history, other conditions, earlier treatments and your preferences. Do not choose an injection or infusion because another patient uses a particular brand. Biologic classes differ. Targeted oral JAK inhibitors are not biologics and require a separate safety discussion [7,10].
For the broader sequence of RA medicines, start with our RA treatment and monitoring guide. This page concentrates on preparation before the first dose and the first follow-up period. Write your questions in advance and bring your medicine list and previous test results if available. A short written list helps prevent an important detail being lost during the consultation.
Bring a complete medicine and health history
Before a medicine is selected, bring a list of everything you take for RA, including methotrexate, steroids and pain medicines, plus medicines for other conditions and supplements. Record when you last received a previous biologic, if any, and whether it caused infection, allergy or monitoring problems. Similar brand names are easy to confuse; bring packages or prescription photos and ask a pharmacist about duplicate ingredients. Combining certain biologics can increase infection risk, and the timing of a switch needs written clinical instructions [3,4].
Mention repeated infections, an admission for infection, prior TB or close TB contact, known hepatitis, lung problems, previous cancer, heart failure or a neurological condition where relevant. None of these details automatically bans every biologic. They change the discussion, may call for specific checks, or make one option less suitable. Also mention frequent travel or past residence where a particular infection is common. EULAR guidance stresses individual risk factors, local context and accompanying medicines, with reassessment over time [1].
If methotrexate remains in your plan, do not stop it simply because a new treatment was discussed. Ask whether the proposed medicine will be added or will replace another, and request clear dose-day and test instructions. Our methotrexate safety and monitoring guide helps with questions about the weekly medicine, but it cannot set your personal switching plan [7].
TB screening: why and how is it reviewed?
Before starting a biologic or related targeted medicine, clinicians commonly assess latent tuberculosis, an older infection that may have no symptoms. EULAR recommends screening before biologic and targeted synthetic DMARDs while also following national guidance. The team may use an IGRA blood test or a skin test according to availability and circumstances, and may need a chest radiograph and exposure history. A negative test does not settle the question of active TB when symptoms or significant exposure are present; your team must interpret the result [1].
Tell the clinician if you were treated for TB, lived with someone who had TB, or have persistent cough, night sweats or unexplained weight loss. Do not hide an old treatment course because you fear postponing the first dose. If latent infection is found, the team decides whether assessment or preventive treatment is needed and when the RA medicine may begin. Timing depends on the infection, medicine and local guidance. Another patient's schedule is not a safe template [1,3].
If a result is unclear or positive, ask who will review it, whether a chest or infection specialist is needed, and when you will return to rheumatology with a shared plan. TB screening is a safety decision, not just an administrative form. Risk may need reassessment later if exposure or other circumstances change during treatment [1].
Hepatitis and other infection checks
Before treatment, tell the clinician about known hepatitis B or C, previous treatment, a relevant older transfusion, or unusual liver results. Some immune-suppressing treatments can reactivate hepatitis B, and the appropriate tests and interpretation depend on the result and proposed medicine. EULAR links preventive management to hepatitis B status before antirheumatic treatment and advises referral for active hepatitis C [1]. This does not mean every person needs an identical test panel or preventive prescription.
The team may discuss HIV testing before some medicines; EULAR recommends it before biologic DMARDs. The purpose is safe care for any infection found, without judgment. Ask what each result means and who will follow up a result requiring liver or infection expertise. If a result is unexpected, do not start or stop treatment based on your own interpretation of a phone screenshot [1].
Mention any active infection now, such as fever with a severe cough, a febrile urinary infection or an infected wound. The team decides when treatment can start after assessment. A minor scratch or mild cold is not automatically equivalent to serious infection, but you need the rule for your specific medicine rather than a guess. Obtain a clear contact route for urgent questions before the first dose [1,3,4].
Review vaccination history before the first dose
Vaccination is part of preparation because infections may be more consequential with RA or immune-suppressing treatment. Bring a vaccination record or any evidence of previous doses. Ask which vaccines fit your age, health, medicine and local schedule. ACR guidance discusses influenza, pneumococcal and shingles vaccination among relevant examples, but the final recommendation and timing vary with prior doses, treatment type and local availability [2].
Some live vaccines need special planning before or during immune-suppressing treatment. Rituximab, for example, can reduce responses to some vaccines, so timing in relation to treatment matters. Do not postpone a medicine dose or change a vaccination date using a general online rule. Request a written plan from the rheumatology team. Mention pregnancy or pregnancy plans and any relevant household vaccine questions so the team can offer tailored advice [2,6].
If you do not remember whether you received a vaccine, say the history is unknown instead of guessing. Ask whether records or a vaccination consultation are needed and when treatment can begin after any recommended vaccine. The aim is a suitable prevention plan, not simply the largest number of injections on one day. Record each vaccine and date alongside your treatment plan [2].
Pregnancy, breastfeeding and family plans
Tell your rheumatologist before treatment selection if pregnancy, pregnancy planning or breastfeeding is relevant. Safety and timing differ between medicines and may also depend on accompanying drugs such as methotrexate. The word 'biologic' does not mean every medicine in the group has the same pregnancy advice. Equally, a pregnancy plan is not a reason to stop all RA treatment suddenly. Disease control matters, and your rheumatologist and obstetric clinician may need a joint plan [8].
Even if pregnancy is not imminent, ask what to do if circumstances change: whom to call, what the team needs to know, and whether accompanying medicines need review before trying. Early discussion gives time to adjust the plan without leaving active disease unattended. If your partner is planning pregnancy while you take RA medicines, mention this too, because the questions differ according to the person taking each medicine [8].
If you are already receiving a biologic and discover a pregnancy, do not use a short online list to decide whether to continue or stop. Contact your team about the specific drug, timing and disease activity. ACR reproductive-health guidance treats pregnancy and breastfeeding medicine decisions individually; drugs within rheumatology treatment groups do not all share the same instructions [8].
Baseline checks depend on the medicine
Ask which baseline tests are needed for the proposed medicine, why each is ordered and who will review it. Checks may include blood counts, liver tests and infection assessment, but there is no identical panel for every medicine or patient. NICE calls for ongoing drug monitoring in RA; your clinician chooses the measures required before and after a particular biologic. An old normal result may not answer a new question if your health has changed [1,7].
Treatment classes differ. TNF inhibitors act on one inflammatory pathway; abatacept has another mechanism; tocilizumab targets IL-6 and has precautions that may include blood count, liver enzymes and lipids. Rituximab brings particular infection, vaccination and hepatitis considerations. These examples explain why checks differ. They are not a menu for selecting a medicine or ordering every possible test without clinical reason [3,4,5,6].
Ask specifically whether liver disease, prior infection, lung problems or an unusual result affects the choice. If a result is abnormal, what is the next step and who owns it? A laboratory number alone is not a start-or-ban decision. Consider the whole plan, including methotrexate or steroids, because monitoring can change when medicines are combined [1,7].
Injection, infusion and the treatment handoff
A biologic may be given as a subcutaneous injection or an intravenous infusion, depending on the product. Before the first dose, ask who will administer it, whether you need hands-on injection training, and how your specific product must be stored and transported. Another patient's technique may not apply. If treatment is given outside the home, clarify who provides it and who reviews you. This article makes no claim that a particular clinic branch gives injections or infusions [3,4,5,6].
Leave with the active ingredient as well as the brand name, route, first and next dates set by your prescriber, and a contact number for problems. We do not give dosing schedules here because they differ. If switching from an older treatment, ask for the last old dose, the first new dose and which accompanying medicines continue. Two boxes at home do not authorize taking both biologics together [4].
If painful hands or weak grip make self-injection difficult, say so before the medicine is supplied; the team can discuss an appropriate method or assistance. Ask what to do if travel, a power failure affecting storage or an unexpected illness interrupts the plan. Do not guess whether an overheated product is usable; consult its leaflet, a pharmacist and your treating team [3].
What if you become ill before a dose?
Before the first dose, obtain written instructions for fever or infection. Some biologics increase the risk of important infections, and the team may postpone a dose in some circumstances until assessment and treatment. The decision depends on symptoms, medicine and dose timing. Contact your team rather than taking the dose or stopping the plan on your own. Report persistent fever, a significant cough, breathlessness, fever with urinary symptoms, an infected wound or antibiotics started by another clinician [1,3,4].
Seek urgent care immediately for severe breathlessness, confusion, chest pain or rapid deterioration with fever. Do not wait for a routine message or a distant review appointment. A hot swollen joint together with systemic illness also needs urgent assessment for possible joint infection; every painful joint in someone with RA is not automatically an ordinary flare [7].
After the infection is assessed, ask when the treatment plan can resume and whether any tests or review are needed. A blanket rule such as 'wait a week' or 'always continue' may be wrong for your medicine and condition. Keep the drug name on your phone and tell any clinician treating an infection about it, the last dose and any other immune-suppressing treatment [1,3].
After starting: response and safety follow-up
Before starting, agree on a follow-up date and what will be measured: joints, pain, daily function and any medicine-specific tests. Ask who communicates abnormal results. RA care aims to reduce disease activity while maintaining safety, and medicine monitoring continues over time. NICE calls for rapid specialist access during flares, clear contact information and ongoing drug monitoring [7].
After treatment starts, note fevers, infections, injection or infusion reactions, and changes in your ability to use your hands, walk or sleep. A brief record is more useful than trying to remember every day at an appointment. Some medicines have particular checks or warning signs. Tocilizumab, for example, makes new abdominal pain important to discuss; rituximab brings infection and vaccination considerations. Ask for the warning signs of your actual medicine rather than relying on a general list [5,6].
If you do not feel better immediately, do not double a dose or add another biologic. Response review timing depends on the medicine and plan, and the team may need to distinguish active inflammation from other causes of pain. Contact them before the planned visit if symptoms worsen or a concerning adverse effect appears. Follow-up is meant to adjust the plan safely, not to prove that one medicine works for everyone [7,10].
A question sheet to take to the appointment
Write five questions at the bottom of your page and seek specific answers: why is a biologic appropriate now; which checks are needed before starting and who reviews them; does your vaccination record need attention; what is the plan for infection; and when will response and safety tests be reviewed? Also confirm the active ingredient and route, the last old dose and first new dose if switching [1,2,7].
Bring a medicine list, earlier results, vaccination record, and dates of previous infections or TB or hepatitis treatment if relevant. If some records are unavailable, say so; the team can decide what must be recovered or repeated. Mention pregnancy plans, frequent travel and difficulty injecting because of hand symptoms. The aim is a decision based on accurate information rather than guesses or general internet instructions [1,8].
If you want to discuss these questions with a La Rose rheumatologist, use the booking page. Arrange a consultation about your individual plan, not a request for a particular drug without assessment. If you have high fever with rapid deterioration or severe breathlessness, seek urgent care rather than waiting for a routine visit. Keep a copy of the written plan and contact number easy to find [3,7].
